LEADER 04382nam 2200589 450 001 9910463038703321 005 20200311153802.0 010 $a1-912530-37-6 010 $a1-908230-85-1 035 $a(CKB)2670000000427609 035 $a(EBL)1938095 035 $a(SSID)ssj0001127788 035 $a(PQKBManifestationID)11634202 035 $a(PQKBTitleCode)TC0001127788 035 $a(PQKBWorkID)11151873 035 $a(PQKB)10001358 035 $a(MiAaPQ)EBC1938095 035 $a(MiAaPQ)EBC6031536 035 $a(Au-PeEL)EBL6031536 035 $a(OCoLC)880720215 035 $a(EXLCZ)992670000000427609 100 $a20200311d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCytomegaloviruses$hVolume II $efrom molecular pathogenesis to intervention /$fedited by Matthias J. Reddehase ; with the assistance of Niels A.W. Lemmermann 210 1$aNorfolk, England :$cCaister Academic Press,$d[2013] 210 4$dİ2013 215 $a1 online resource (559 p.) 300 $aDescription based upon print version of record. 311 $a1-908230-20-7 320 $aIncludes bibliographical references and indexes. 327 $aContents Volume II; Abbreviations used in Volume II; Ch II.1: Synopsis of Clinical Aspects of Human Cytomegalovirus Disease; Ch II.2: The Epidemiology and Public Health Impact of Congenital Cytomegalovirus Infection; Ch II.2 - Addendum: The Economic Impact of Congenital CMV Infection: Methods and Estimates; Ch II. 3: Clinical Cytomegalovirus Research: Congenital Infection; Ch II. 4: Cytomegalovirus Replication in the II.4Developing Human Placenta; Ch II.5: The Guinea Pig Model of Congenital Cytomegalovirus Infection; Ch II. 6: Murine Model of Neonatal Cytomegalovirus Infection 327 $aCh II.7: Adaptive Cellular Immunity to Human II.7CytomegalovirusCh II.8: Natural Killers Cells and Human Cytomegalovirus; Ch II.9: Innate Immunity to Cytomegalovirus in the Murine Model; Ch II.10: Protective Humoral Immunity; Ch II.11: Immunoregulatory Cytokine Networks Discovered and Characterized during Murine Cytomegalovirus Infections; Ch II.12: Host Genetic Models in Cytomegalovirus Immunology; Ch II.13: Clinical Cytomegalovirus Research: Thoracic Organ Transplantation; Ch II.14: Clinical Cytomegalovirus Research: Liver and Kidney Transplantation 327 $aCh II.15: The Rat Model of Cytomegalovirus Infection and Vascular DiseaseCh II.16: Clinical Cytomegalovirus Research: Haematopoietic Cell Transplantation; Ch II.17: Murine Model for Cytoimmunotherapy of CMV Disease after Haematopoietic Cell Transplantation; Ch II.18: State of the Art and Trends in Cytomegalovirus Diagnostics; Ch II.19: Antiviral Therapy, Drug Resistance and Computed Resistance Profiling; Ch II 20: Cytomegalovirus Vaccine: On the Way to the Future?; Ch II.21: Vaccine Vectors Using the Unique Biology and Immunology of Cytomegalovirus 327 $aCh II.22: Non-Human-Primate Models of Cytomegalovirus Infection, Prevention, and TherapyCh II. 23: Putative Disease Associations with Cytomegalovirus: a Critical Survey; Epilogue - Re?sume? and Visions: From CMV Todayto CMV Tomorrow; Subject index; Open reading frame index; Cluster of differentiation index; CMV strains index; Antiviral drugs index; Frequently discussed molecules 330 $aHuman Cytomegalovirus (CMV) - a member of the herpesvirus family - is an underrated health risk. A low public awareness results from the relatively mild symptoms it causes in otherwise healthy people whose immune systems are intact, with primary infection usually going unnoticed. During pregnancy, however, transmission from the mother to the fetus is currently the most frequent viral cause of birth defects with lifelong neurological sequelae, sensorineural hearing loss in particular. People at risk also include the growing number of immune compromised patients requiring either a solid organ gr 606 $aCytomegalovirus infections 608 $aElectronic books. 615 0$aCytomegalovirus infections. 676 $a616.925 702 $aReddehase$b Matthias J. 702 $aLemmermann$b Niels 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910463038703321 996 $aCytomegaloviruses$92138481 997 $aUNINA LEADER 05391nam 2201633z- 450 001 9910367743903321 005 20210211 010 $a3-03921-655-4 035 $a(CKB)4100000010106278 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/56155 035 $a(oapen)doab56155 035 $a(EXLCZ)994100000010106278 100 $a20202102d2019 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPheochromocytoma (PHEO) and Paraganglioma (PGL) 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 215 $a1 online resource (380 p.) 311 08$a3-03921-654-6 330 $aThis book outlines some new advances in genetics, clinical evaluation, localization, therapy (newly including immunotherapy) of pheochromocytoma and paraganglioma including their metastatic counterparts. Well-known and experienced clinicians and scientists contributed to this book to include some novel approaches to these tumors. This book will serve to various health care professionals from different subspecialties, but mainly oncologists, endocrinologists, endocrine surgeons, pediatricians, and radiologists. This book shows that the field of pheochromocytoma/paraganglioma is evolving and a significant progress has been made in last 5 years requiring that health care professionals and scientists will learns new information and implement it in their clinical practice or scientific work, respectively. This book should not be missed by anybody who is focusing on neuroendocrine tumors, their newest evaluation and treatment. 517 $aPheochromocytoma 606 $aMedicine and Nursing$2bicssc 610 $a11C-hydroxy-ephedrine 610 $a177Lu-DOTATATE 610 $a18F-FDOPA 610 $aadaptive immunity 610 $aadrenal incidentaloma 610 $aadrenal tumor 610 $aadrenocortical carcinoma 610 $aadrenomedullary function 610 $aangiogenesis 610 $aarrhythmia 610 $aaverage real variability 610 $ablood pressure variability 610 $acalorimetry 610 $acarotid body 610 $acatecholamine 610 $acatecholamines 610 $achromogranin A 610 $achromosomal alteration 610 $aCNV detection 610 $acomparative genomics 610 $acryoablation 610 $adiabetes mellitus 610 $adog 610 $aectopic secretion 610 $aenergy metabolism 610 $aEPAS1 610 $aerythropoietin 610 $aFGF21 610 $afluorescence imaging 610 $aGAPP 610 $agermline mutation 610 $aglobal longitudinal strain 610 $aGTV 610 $ahead and neck 610 $ahereditary 610 $aHIF 610 $ahistology 610 $ahypertension 610 $ahypotension 610 $ahypoxia 610 $ahypoxia-inducible factor 610 $aimmunohistochemistry 610 $aimmunotherapy 610 $ainflammation 610 $ainnate immunity 610 $alL-6 610 $ameta-analysis 610 $ametanephrines 610 $ametastatic 610 $ametastatic OR malignant pheochromocytoma 610 $aminimally invasive procedure 610 $amitochondria 610 $amortality 610 $amouse pheochromocytoma cells 610 $amutation 610 $an/a 610 $aNET 610 $aneural crest 610 $aneuroendocrine 610 $aneuroendocrine tumor 610 $aneurogenesis 610 $aneutrophil 610 $anext-generation sequencing 610 $aNF1 610 $anormetanephrines 610 $aobesity 610 $apan-cancer analysis 610 $aparaganglioma 610 $aPASS 610 $apathogen-associated molecular patterns 610 $aPCC 610 $apeptide receptor radiotherapy 610 $apercutaneous ablation 610 $apercutaneous ethanol injection 610 $aPET 610 $aPET-CT 610 $aPGL 610 $apheochromocytoma 610 $apheochromocytoma and paraganglioma 610 $aphosphorylation tyrosine hydroxylase 610 $apolycythemia 610 $apostoperative 610 $aPPGL 610 $aPRRT 610 $apseudohypoxia 610 $aradiofrequency ablation 610 $aradiosensitization 610 $aradiotherapy 610 $aSDHB 610 $aSDHD 610 $asomatostatinoma 610 $aspeckle-tracking echocardiography 610 $aspheroids 610 $asporadic 610 $astem-like tumor cells 610 $asubclinical systolic dysfunction 610 $asuccinate dehydrogenase 610 $aT cell 610 $atargeted therapy 610 $aTCA cycle 610 $atherapy resistance 610 $atoll-like receptor 610 $atransgenic mice 610 $avasculogenesis 610 $aVHL 610 $aweighted standard deviation 610 $axenograft 615 7$aMedicine and Nursing 700 $aPacak$b Karel$4auth$0881323 702 $aTai?eb$b David$4auth 906 $aBOOK 912 $a9910367743903321 996 $aPheochromocytoma (PHEO) and Paraganglioma (PGL)$93030537 997 $aUNINA